TABLE 3.
List of PROTACs or heterobifunctional degraders in clinical trials (accessed from clinicaltrials.gov as of December 2021)
| Clinical Trial Identifier | Target | Compound | Disease/Condition | Phase |
|---|---|---|---|---|
| NCT03888612 | Androgen Receptor | ARV-110 | Metastatic Castration Resistant Prostate Cancer | Phase 2 |
| NCT05067140 | Androgen Receptor | ARV-766 | Metastatic Castration Resistant Prostate Cancer | Phase 1 |
| NCT04428788 | Androgen Receptor | CC-94676 | Metastatic Castration-Resistant Prostate Cancer | Phase 1 |
| NCT04886622 | BCL-xL (BCL2L1) | DT2216 | Relapsed/Refractory Malignancies | Phase 1 |
| NCT04965753 | BRD9 | FHD-609 | Advanced Synovial Sarcoma | Phase 1 |
| NCT05006716 | BTK | BGB-16673 | B-Cell Malignancies | Phase 1 |
| NCT04830137 | BTK | NX-2127 | Relapsed/Refractory B-cell Malignancies | Phase 1 |
| NCT05131022 | BTK | NX-5948 | Relapsed/Refractory B-cell Malignancies | Phase 1 |
| NCT04072952 | Estrogen Receptor | ARV-471 | ER+/HER2- Locally Advanced or Metastatic Breast Cancer | Phase 1/2 |
| NCT04772885 | IRAK4 | KT-474 | Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS) | Phase 1 |